Business
-
Takeda Pharmaceutical has announced that it will lay off approximately 2,800 employees — 2,100 in Europe and 700 in the US — as it realigns to accommodate its 2011 acquisition of Nycomed. Nycomed’s products include… Read more . . .
-
After the rejection of its last offer in December, Valeant Pharmaceuticals says that it has increased its offer for ISTA to $7.50 per share from $6.50 and adds that it has informed ISTA that the… Read more . . .
-
A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by… Read more . . .
-
According to an interim management statement released by Vectura, the company anticipates a cut R&D expenditures by £1m for the fiscal year ending March 31 2012 and expects additional cuts for FY2013. The company said,… Read more . . .
-
Fleming Pharmaceuticals says that it sold the rights to its Ocean brand saline nasal products, along with three other products, to Valeant, which will distribute the product through Valeant Pharmaceuticals North America LLC. Ocean nasal… Read more . . .
-
California pharmaceutical company Inverseon has announced that it will redirect its development program for INV102, an inverse beta agonist, to focus on smoking cessation and COPD rather than asthma, although it is continuing to seek… Read more . . .
-
Mumbai-based pharmaceutical and biotechnology company Wockhardt says that it will launch its generic version of GSK’s Flonase fluticasone nasal spray in the US immediately after having received approval from the US FDA. The company will… Read more . . .
-
Launched officially on January 1, 2012, Lustren Consulting is now offering “specialist management consultancy for device development in the healthcare industry” with particular expertise in inhalation device development. The company, which was unofficially introduced at… Read more . . .
-
The European Patent Office has granted patent number EP 2315580 B1 to Massachusetts biotech company Pulmatrix for “Pharmaceutical formulations and methods for treating respiratory tract infections.” The patent covers “both dry powder and liquid formulations… Read more . . .
-
California-based Elevation Pharmaceuticals has announced closing of $30 million in Series B financing for development of its lead product, EP-101, a glycopyrrolate inhalation solution for the treatment of COPD. Novo Ventures, a new investor, led… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden